LLY241206C895000
- 0.01
- 0.000.00%
Eli Lilly and Co Newsroom
Bank of America: Resuming coverage of Eli Lilly and Co, rating it as 'Buy'.
Bank of America resumes coverage on Eli Lilly and Co, assigning a "Buy" rating with a Target Price of $997.
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $997
Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.
Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
What's Going On With Eli Lilly Stock On Tuesday?
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Eli Lilly and Company (LLY) Is Attracting Investor Attention: Here Is What You Should Know
Market-Moving News for December 10th
Express News | B of A Securities Reinstates Buy on Eli Lilly, Announces $997 Price Target
Eli Lilly Analyst Ratings
As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
Eli Lilly Declares Higher Dividend for Fiscal Q1
Eli Lilly and Co To Go Ex-Dividend On February 14th, 2025 With 1.5 USD Dividend Per Share
Eli Lilly Reports Results From Phase 3 BRUIN CLL-321 Trial Evaluating Pirtobrutinib; Study's Primary Endpoint Of Progression-Free Survival Was Met At Primary Analysis
Eli Lilly Shares Are Trading Higher After the Company Announced a Share Repurchase Program and Dividend Increase.
Press Release: Lilly Announces New $15 Billion Share Repurchase Program and Seventh Consecutive 15% Dividend Increase